Long-term dupilumab effect on lung function in paediatric patients with uncontrolled asthma

Introduction: Minimizing lung function impairment is a goal to managing paediatric asthma. Dupilumab (DPL), a fully human monoclonal antibody, blocks the shared receptor component of IL-4/IL-13, key drivers of type 2 asthma. Long-term DPL use in EXCURSION (NCT03560466) sustained lung function improvement in 6–11-year-old patients (pts) with uncontrolled type 2 asthma who had completed VOYAGE (NCT02948959); rapid improvement in lung function was observed in patients who switched from placebo (PBO) to DPL. This analysis assessed numerically higher lung function improvements seen consistently in the DPL/DPL vs PBO/DPL arms in EXCURSION.